tech. enhancements -- half-life/stealthing

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
tech. enhancements -- half-life/stealthing

An SI Board Since February 2001

Posts	SubjectMarks	Bans	Symbol
53	10	0	VLTS

Emcee: scaram(o)uche	Type: Moderated

Introduction Market Data Compact

scrapbook for stuff relating to half-life extension, PEGylation, inhibition of immunogenicity, etc.

signalsmag.com

As an example, Mayer pointed to HGS' recent acquisition of
Principia Pharmaceutical Corp., completed in September 2000. "We
acquired it with stock [$120 million], but we knew we had to invest
[money] in the technology to move ahead quickly." And, it's done just
that.

Principia's forte is its recombinant albumin fusion technology, by
which therapeutic proteins are genetically fused to albumin,
prolonging their circulation in the bloodstream. And HGS has already
found the technology extremely useful in its own R&D programs: It's
filed one IND (albuferon for treating HCV) and is ready to file a
second one (albumin-hGH for growth hormone deficiencies),
according to Mayer. He added that HGS will also employ the albumin
fusion technology in its peptide-drug collaboration with Dyax Corp.
It's become such an integral part of the business that HGS is also
moving Principia from Norristown, PA to Rockville this summer.
Going forward, Mayer said, "We'll continue to seek to acquire rights
to new products and technologies," probably with equity rather than
cash.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
53	Domantis Granted Broad European Patent Rights to Pioneering Half-Life Extension	nigel bates	-	6/20/2006
52	Old spinout from vrtx, worth keeping an eye on imo. Press Release Source: Altu	rkrw	-	6/6/2005
51	[New CPEs for transdermal delivery] >>Published online before print March	tuck	-	3/17/2005
50	DAC(TM):GRF is a chemically modified form of GRF that, followingsubcutaneous inj	scaram(o)uche	-	12/9/2004
49	<pre>ConjuChem Successfully Completes Phase I Multi-dose Trial for DAC(TM)	keokalani'nui	-	12/9/2004
48	XenoPort, Inc. Names William J. Rieflin, Former Tularik Executive, As President	nigel bates	-	12/3/2004
47	TransForm Receives Milestone Payment from AstraZeneca LEXINGTON, Mass.--(BUSINE	nigel bates	-	12/1/2004
46	Fun. Thanks for posting that. (eom)	scaram(o)uche	-	11/2/2004
45	[Regulated long-term delivery of therapeutic proteins by using antigen-specific	tuck	-	11/1/2004
44	Corgentech Licenses Novel Peptide Delivery System From Cyclacel to Assist System	nigel bates	-	9/27/2004
43	BioRexis, transferrin conjugates??...... Message 19903855	scaram(o)uche	-	3/11/2004
42	Message 19835730	scaram(o)uche	-	3/1/2004
41	Message 19828314	scaram(o)uche	-	2/22/2004
40	Parking: novosom.de	nigel bates	-	1/17/2004
39	XenoPort Reports Positive Results from Its Initial Phase I Study of XP13512, a N	nigel bates	-	1/12/2004
38	Papers In Press, published online ahead of print December 29, 2003 J. Biol. Chem	scaram(o)uche	-	12/31/2003
37	PNAS Study from BioMarin Highlights Possible New Approach for Improving the Effi	scaram(o)uche	-	12/29/2003
36	Corante Blogger on the difficulty of fine-tuning solubilty of therapeutics (with	tuck	-	12/16/2003
35	Thanks for the link; hadn't seen that. I got a bit interested in Phogen (par	nigel bates	-	9/30/2003
34	And one more, a more recent one, about dendrimers for delivery: pubs.acs.org C	tuck	-	9/30/2003
33	Wasn't sure where to put this, but this thread seems to be focused in improv	tuck	-	9/30/2003
32	Try looking in the '03 AACR meeting planner under "Enhanced Drug Delive	tuck	-	3/20/2003
31	[polyglutamate + paclitaxel versus solid tumors ==> CTIC] clincancerres.aacr	tuck	-	3/20/2003
30	Very interesting method for crossing the BBB: <i>Global non-viral gene t	nigel bates	-	3/20/2003
29	NPS Pharmaceuticals and Enzon Pharmaceuticals Agree to Merger of Equals Thursday	scaram(o)uche	-	2/20/2003

Go to reply# or date (mm/dd/yy):